A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

US biotech Incyte (Nasdaq: INCY) yesterday announced positive top-line results from the pivotal Phase III frontMIND trial ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue. There’s a need for access to treatment and a need for better drugs in diffuse large B-cell lymphoma ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Diffuse large B-cell lymphoma (DLBCL) account for approximately 40% of adult non-Hodgkin lymphomas. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large ...

Diffuse lymphomas of B-cell origin represent a heterogeneous group of lymphoid neoplasms. The histologically aggressive subtypes of diffuse B-cell lymphomas include biologically different entities, ...

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...